基于激素的设计和优化tecovirimat衍生品作为强大的抗病毒药物对抗水病毒病毒
Yuanguang Chen1, Sumei Yang2, Xingyu Zhou3
1Shenzhen Key Laboratory of Small Molecule Drug Discovery and Synthesis, Department of Chemistry, Shenzhen Grubbs Institute and Medi-X Pingshan, Southern University of Science and Technology, Shenzhen, 518000, China; Shenzhen AntiV Pharma Co., Ltd., Shenzhen, Guangdong, 518081, China.
European journal of medicinal chemistry
|December 14, 2025
概括
研究人员开发了新型的tecovirimat衍生物来对抗麻疹病毒 (MPXV) 爆发. 一个有前途的化合物,C12,在临床前研究中显示出强大的抗病毒活性,良好的生物可用性和低毒性.
科学领域:
- 病毒学 病毒学
- 药用化学 医学化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 麻疹病毒 (MPXV) 构成了严重的全球健康威胁,需要有效的抗病毒治疗.
- 德科维里马特是一种FDA批准的抗病毒药物,向MPXV p37蛋白质,这对病毒输出至关重要.
- 现有的治疗方法强调了需要可访问的MPXV抑制剂和详细的结构-活性关系 (SAR) 研究.
研究的目的:
- 为潜在的MPXV治疗设计和合成新型特科维里马特衍生物.
- 评估这些新化合物的抗病毒疗效和安全性.
- 研究作用机制,指导下一代抗病毒药物的开发.
主要方法:
- 一个新的tecovirimat衍生物库的合成.
- 表型查以确定抗病毒活性 (EC50) 和细胞毒性 (CC50).
- 在小鼠体内药理动力学研究 (生物可用性,血暴露) 和毒性评估.
- 使用疫苗病毒 (VACV) P37蛋白质结构的分子对接模拟.
主要成果:
- 化合物C12的鉴定是具有EC50=12.14nM和CC50=304.63μM的强.
- 在小鼠中,C12表现出极好的口服生物利用率 (162%) 和广泛的血分布.
- 临床前研究表明,C12在小鼠中具有低毒性和良好的耐受性.
- 分子对接表明C12向与tecovirimat相同的P37蛋白质.
结论:
- 化合物C12代表了MPXV的下一代有希望的抗病毒候选人.
- 这项研究为合理设计新型骨质疏松病毒抑制剂提供了宝贵的见解.
- 进一步开发C12可能会导致对MPXV感染的更容易获得和更有效的治疗方法.
更多相关视频
相关概念视频
Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Inhibitors Of Virion Release
Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...
Antiviral Nucleoside Inhibitors
Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Inhibitors of Virion Maturation and Assembly
As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...
Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...


